This advisory summarizes data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder.
Order Print Publication
You May Also Be Interested In
Clinical Guidance for Treating Pregnant and Parenting Women With Opioid Use Disorder and Their Infants
This Clinical Guide provides comprehensive, national guidance for optimal management of pregnant and parenting women with opioid use disorder and their infants. The Clinical Guide helps healthcare professionals and patients determine the most clinically appropriate action for a particular situation and informs individualized treatment decisions.
Use of Medication-Assisted Treatment in Emergency Departments
This guide examines emerging and best practices for initiating medication-assisted treatment in emergency departments. It also reviews the existing literature and science of the topic, identifies gaps in knowledge, and discusses challenges of implementation.
Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs
This guide informs clinicians about medications for opioid use disorder treatment, including side effects, drug interactions, and take-home doses. It discusses patient counseling, associated medical issues, hepatitis C evaluation, drug testing, and pregnant women.
The Facts about Buprenorphine for Treatment of Opioid Addiction
This brochure informs patients about buprenorphine and medication-assisted treatment for opioid use disorder. It describes addiction and withdrawal, how buprenorphine works, its proper use, its side effects, and how it fits with counseling in the recovery process.
Behavioral Health Equity Barometer, 2014
This report provides a snapshot of key aspects of behavioral health, serious mental illness, suicidal thoughts, and mental illness, substance use disorders, or both. The information is based on selected determinants of health, including race and ethnicity, income level, geography, and health insurance status.
TIP 63: Medications for Opioid Use Disorder - Full Document
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.